
Fabry Disease Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease
Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease Fabry Disease Sangamo Therapeutics a genomic medicine company, has announced updated results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), its proprietary gene therapy candidate for Fabry disease.…